Clinical Trials

Melanoma, Neoplasms

NCT06307093 2024-03-12

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

DermatologicHead & NeckThoracic

90 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Lung Neoplasms, Melanoma, Neoplasms

NCT04544748 2024-03-06

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies

DermatologicGenitourinaryThoracic

48 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Histologic Type, Urologic Neoplasms

NCT04879654 2024-03-05

SNMM

45 enrolled

Melanoma

NCT05135715 2024-02-20

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

50 enrolled

Melanoma

NCT06254547 2024-02-12

Leaderboard Influence on Self-Regulated Training in a Gamified Dermoscopy Training App

150 enrolled

Melanoma, Skin Neoplasms

NCT04702854 2024-02-09

BMUMM

60 enrolled

Melanoma

NCT04137900 2024-02-05

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

DermatologicLymphoidThoracic

499 enrolled

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Neoplasm Metastasis

NCT06239623 2024-02-02

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

60 enrolled

Melanoma

NCT06236360 2024-02-01

MINI-MD

30 enrolled

Melanoma, Neoplasm Metastasis

NCT06207747 2024-01-17

Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma Patients

70 enrolled

Melanoma

NCT04720768 2024-01-05

CELEBRATE

78 enrolled

Melanoma, Neoplasm Metastasis

NCT03638375 2023-12-12

ACTME

34 enrolled

Melanoma, Drug-Related Side Effects and Adverse Reactions

NCT02557321 2023-11-21

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

50 enrolled

Melanoma

NCT02977052 2023-11-15

OpACIN-neo

186 enrolled

Melanoma

NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

DermatologicHead & NeckSarcomaThoracic

172 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT05370807 2023-10-24

RegoMel

48 enrolled

Melanoma

NCT04670445 2023-10-23

UPLIFT

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

210 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Melanoma, Mesothelioma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

NCT04201223 2023-10-18

FLARE

762 enrolled

Melanoma

NCT06080711 2023-10-12

AIDMel

30 enrolled

Melanoma, Skin Neoplasms

NCT04546074 2023-10-03

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

22 enrolled

Melanoma

NCT01586767 2023-09-21

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

45 enrolled

CNSDermatologic

Sinonasal undifferentiated carcinoma, Carcinoma, Squamous Cell, Carcinoma, Adenoid Cystic, Fistula, Melanoma, Carcinoma, Mucoepidermoid, Esthesioneuroblastoma, Olfactory

NCT04986696 2023-09-21

IMPulse

46 enrolled

Disease, Melanoma

NCT05986331 2023-09-21

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Phase 3 Unknown

366 enrolled

Melanoma

NCT02858921 2023-08-30

Neo Trio

60 enrolled

Melanoma, Neoplasms

NCT03808441 2023-08-25

CAcTUS

21 enrolled

Melanoma

NCT05990634 2023-08-14

LifeChamps Feasibility Study

20 enrolled

Melanoma, Neoplasms

NCT05739006 2023-08-02

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

131 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

314 enrolled

Breast Neoplasms, Carcinoma, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

6 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05928962 2023-07-10

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

10 enrolled

Melanoma

NCT04763083 2023-07-07

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

DermatologicLymphoidOther hematologic neoplasmThoracic

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lymphoma, Follicular, Melanoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05451407 2023-07-07

Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

50 enrolled

Melanoma

NCT03803397 2023-07-06

Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma

10 enrolled

Melanoma

NCT05827289 2023-07-06

CAPABLE

36 enrolled

Melanoma

NCT05907512 2023-06-22

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

43 enrolled

Melanoma

NCT05478473 2023-06-18

Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma

43 enrolled

Melanoma

NCT05906277 2023-06-15

Melamoma4p

300 enrolled

Melanoma

NCT05106023 2023-06-07

To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

31 enrolled

Melanoma

NCT04631731 2023-06-01

ICEMELT